Literature DB >> 24055850

Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS.

Jia-Hua Zheng1, Louis A Guida, Caitlin Rower, Jose Castillo-Mancilla, Amie Meditz, Brandon Klein, Becky Jo Kerr, Jacob Langness, Lane Bushman, Jennifer Kiser, Peter L Anderson.   

Abstract

A reversed-phase high performance liquid chromatographic (LC), tandem mass spectrometry (MS/MS) assay for the determination of tenofovir (TFV) and emtricitabine (FTC) in dried blood spots (DBS) from human whole blood was developed and validated. Whole blood samples were spotted, dried, and a 3mm punch was extracted with methanol for analysis by LC-MS/MS utilizing stable isotope labeled internal standards. The assay was validated over the range of 2.5-1000ng/mL for TFV and 2.5-5000ng/mL for FTC. The method was accurate (within ±15% of control) and precise (coefficient of variation ≤15%) for hematocrit concentrations ranging from 25% to 76%; using edge punches vs. center punches; and spot volumes of 10-50μL. Analytes were stable for five freeze/thaw cycles and up to 6 days at room temperature, whereas long-term storage required -20°C or -80°C. Comparison of TFV and FTC in DBS vs. plasma yielded r(2)≥0.96, indicating that DBS can be used as a plasma alternative for pharmacokinetic analyses in vivo.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Analytical method; Antiretroviral therapy; Dried blood spot; LC–MS/MS; Nucleoside analog

Mesh:

Substances:

Year:  2013        PMID: 24055850      PMCID: PMC3842403          DOI: 10.1016/j.jpba.2013.08.033

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  15 in total

1.  Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS.

Authors:  B K Matuszewski; M L Constanzer; C M Chavez-Eng
Journal:  Anal Chem       Date:  2003-07-01       Impact factor: 6.986

Review 2.  Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules.

Authors:  Wenkui Li; Francis L S Tse
Journal:  Biomed Chromatogr       Date:  2010-01       Impact factor: 1.902

3.  Internal standard tracked dilution to overcome challenges in dried blood spots and robotic sample preparation for liquid chromatography/tandem mass spectrometry assays.

Authors:  Guowen Liu; Heidi M Snapp; Qin C Ji
Journal:  Rapid Commun Mass Spectrom       Date:  2011-05-15       Impact factor: 2.419

4.  Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.

Authors:  Jennifer R King; Ram Yogev; Patrick Jean-Philippe; Bobbie Graham; Andrew Wiznia; Paula Britto; Vincent Carey; Rohan Hazra; Edward P Acosta
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

5.  Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

Authors:  Jose R Castillo-Mancilla; Jia-Hua Zheng; Joseph E Rower; Amie Meditz; Edward M Gardner; Julie Predhomme; Caitlin Fernandez; Jacob Langness; Jennifer J Kiser; Lane R Bushman; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-10       Impact factor: 2.205

6.  Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection.

Authors:  Lane R Bushman; Jennifer J Kiser; Joseph E Rower; Brandon Klein; Jia-Hua Zheng; Michelle L Ray; Peter L Anderson
Journal:  J Pharm Biomed Anal       Date:  2011-06-06       Impact factor: 3.935

7.  Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.

Authors:  Lucie Durand-Gasselin; David Da Silva; Henri Benech; Alain Pruvost; Jacques Grassi
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

8.  Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).

Authors:  Déborah Hirt; Didier K Ekouévi; Alain Pruvost; Saïk Urien; Elise Arrivé; Stéphane Blanche; Divine Avit; Clarisse Amani-Bosse; Mandisa Nyati; Shini Legote; Meng L Ek; Leakhena Say; James McIntyre; François Dabis; Jean-Marc Tréluyer
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

9.  Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.

Authors:  Patricia M Flynn; Mark Mirochnick; David E Shapiro; Arlene Bardeguez; John Rodman; Brian Robbins; Sharon Huang; Susan A Fiscus; Koen K A Van Rompay; James F Rooney; Brian Kearney; Lynne M Mofenson; D Heather Watts; Patrick Jean-Philippe; Barbara Heckman; Edwin Thorpe; Amanda Cotter; Murli Purswani
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

10.  Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of tenofovir and emtricitabine in human plasma and its application to a bioequivalence study.

Authors:  Noel A Gomes; Vikas V Vaidya; Ashutosh Pudage; Santosh S Joshi; Sagar A Parekh
Journal:  J Pharm Biomed Anal       Date:  2008-08-05       Impact factor: 3.935

View more
  23 in total

1.  Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.

Authors:  Roman Shrestha; Frederick L Altice; Brian Sibilio; Jude Ssenyonjo; Michael M Copenhaver
Journal:  Contemp Clin Trials       Date:  2019-06-20       Impact factor: 2.226

2.  LC-MS/MS method for the simultaneous determination of tenofovir, emtricitabine, elvitegravir and rilpivirine in dried blood spots.

Authors:  Pavan Kumar Prathipati; Subhra Mandal; Christopher J Destache
Journal:  Biomed Chromatogr       Date:  2018-04-26       Impact factor: 1.902

3.  A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells.

Authors:  Leah C Jimmerson; Lane R Bushman; Michelle L Ray; Peter L Anderson; Jennifer J Kiser
Journal:  Pharm Res       Date:  2016-09-15       Impact factor: 4.200

4.  Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery.

Authors:  Susanne Doblecki-Lewis; Stephanie Cohen; Albert Liu
Journal:  Curr Treat Options Infect Dis       Date:  2015-06

5.  Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.

Authors:  H C Koenig; K Mounzer; G W Daughtridge; C E Sloan; L Lalley-Chareczko; G S Moorthy; S C Conyngham; A F Zuppa; L J Montaner; P Tebas
Journal:  HIV Med       Date:  2017-04-26       Impact factor: 3.180

6.  Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.

Authors:  Richard E Haaland; Amy Martin; Tamee Livermont; Jeffrey Fountain; Chuong Dinh; Angela Holder; Lindsey D Lupo; LaShonda Hall; Christopher Conway-Washington; Colleen F Kelley
Journal:  J Acquir Immune Defic Syndr       Date:  2019-11-01       Impact factor: 3.731

7.  Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression.

Authors:  Tammy C Wong; Audrey Lan; Jennifer J Kiser; Peter L Anderson; Keyur Patel; Hans Tillman; Susanna Naggie
Journal:  Hepatology       Date:  2016-03-18       Impact factor: 17.425

Review 8.  Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring.

Authors:  Jose R Castillo-Mancilla; Jessica E Haberer
Journal:  Curr HIV/AIDS Rep       Date:  2018-02       Impact factor: 5.071

9.  Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data.

Authors:  Zoë Baker; Marjan Javanbakht; Stan Mierzwa; Craig Pavel; Michelle Lally; Gregory Zimet; Pamina Gorbach
Journal:  AIDS Behav       Date:  2018-04

Review 10.  Therapeutic drug monitoring by dried blood spot: progress to date and future directions.

Authors:  Abraham J Wilhelm; Jeroen C G den Burger; Eleonora L Swart
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.